Estrogens and Parkinson disease: Neuroprotective, symptomatic, neither, or both?

Endocrine

Volumn 21, Issue 1, 2003, Pages 81-87

  Saunders Pullman, Rachel ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Estrogen; Levo dopa; Nigrostriatal system; Parkinson disease; Selective estrogen receptor modulators

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 17ALPHA ESTRADIOL; CAFFEINE; CATECHOL METHYLTRANSFERASE; CONJUGATED ESTROGEN; DOPAMINE; DOPAMINE RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; LEVODOPA; NEUROTROPHIC FACTOR; OXIDOPAMINE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; BINDING AFFINITY; BRADYKINESIA; BREAST CANCER; CELL SURVIVAL; CELL VIABILITY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DYSKINESIA; ENZYME ACTIVITY; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; HORMONE ACTION; HUMAN; LABORATORY TEST; LOW DRUG DOSE; MENOPAUSE; MODULATION; MOTOR PERFORMANCE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OVARIECTOMY; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SMOKING; STEREOSPECIFICITY; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; TREMOR; TYPES OF STUDY; VENTRAL TEGMENTUM;

EID: 0037606126     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1385/ENDO:21:1:81     Document Type: Review

References (70)

1. Mahant, P. and Stacy, M. (2001). Neurol. Clin. 19, 553-563.
2. Baldereschi, M., Di Carlo, A., Rocca, W. A., et al. (2000). Neurology 55, 1358-1363.
3. Bower, J. H., Maraganore, D. M., McDonnell, S. K., and Rocca, W. A. (1999). Neurology 52, 1214-1220.
4. Parkinson's Study Group. (1996). Ann. Neurol. 39, 37-45.
5. Lyons, K. E., Hubble, J. P., Troester, A., Pahwa, R., and Koller, W. C. (1998). Neurology 50, 1323-1326.
6. Garcia-Segura, L. M., Azcoitia, I., and DonCarlos, L. (2001). Prog. Neurobiol. 63, 29-60.
7. Sandyk, R. (1989). Int. J. Neurosci. 45, 119-122.
8. Saunders-Pullman, R., Gordon-Elliott, J., Parides, M., Fahn, S., Saunders, H., and Bressman, S. (1999). Neurology 52, 1417-1421.
9. Tsang, K.-L., Ho, S.-L., and Lo, S.-K. (2000). Neurology 54, 2292-2298.
10. Gibb, W. R. G. and Lees, A. J. (1988). J. Neurol. Neurosurg. Psychiatry 51, 745-752.
11. Gibb, W. R. G., Scott, T., and Lees, A. J. (1991). Mov. Disord. 6, 2-11.
12. Harada, H., Nishikawa, S., and Takahashi, K. (1983). Arch. Neurol. 40, 151-154.
13. Kurland, L. T. (1958). In: Pathogenesis and treatment of parkinsonism. Field, W. (ed.). Charles C Thomas: Springfield, IL.
14. Schoenberg, B. S. (1986). Adv. Neurol. 45, 277-283.
15. Dluzen, D. and McDermott, J. (2000). J. Gender Specific Med. 3, 36-42.
16. Rajput, A. H., Offord, K. P., Beard, C. M., and Kurland, L. T. (1984). Ann. Neurol. 16, 278-283.
17. Toran-Allerand, C., Singh, M., and Setalo, G. (1999). Front. Neuroendocrinol. 20, 97-121.
18. Kuppers, E., Ivanova, T., Karolczak, M., Lazarov, N., Fohr, K., and Beyer, C. (2001). Horm. Behav. 40, 196-202.
19. Zhang, J. Q., Cai, W. Q., Zhou, S., and Su, B. Y. (2002). Brain Res. 935, 73-80.
20. Creutz, L. M. and Kritzer, M. F. (2002). J. Comp. Neurol. 446, 288-300.
21. Nilsen, J., Mor, G., and Naftolin, F. (2000). J. Neurosci. 20, 8604-8609.
22. Wong, M., Thompson, T. L., and Moss, R. L. (1996). Crit. Rev. Neurobiol. 10, 189-203.
23. DiPaolo, T. (1994). Rev. Neurosci. 5, 27-41.
24. Becker, J. B. (1999). Pharmacol. Biochem. Behav. 64, 803-812.
25. van Hartesveldt, C. and Joyce, J. N. (1986). Neurosci. Biobehav. Rev. 10, 1-14.
26. Pasqualini, C., Olivier, V., Guibert, B., Frain, O., and Leviel, V. (1995). J. Neurochem. 65, 1651-1657.
27. McDermott, J. L., Liu, B., and Dluzen, D. E. (1994). Exp. Neurol. 125, 306-311.
28. Morissette, M., Garcia-Segura, L. M., Belanger, A., and Di Paolo, T. (1992). Neuroscience 49, 893-902.
29. Levesque, D. and Di Paolo, T. (1993). Biochem. Pharmacol. 45, 723-733.
30. Roy, E. J., Buyer, D. R., and Licari, V. A. (1990). Brain Res. Bull. 25, 221-227.
31. Hruska, R. E. (1986). J. Neurochem. 47, 1908-1915.
32. Levesque, D. and Di Paolo, T. (1988). Neurosci. Lett. 88, 113-138.
33. Ferreira, A. and Caceres, A. (1991). J. Neurosci. 11, 392-400.
34. Xie, T., Ho, S. L., and Ramsden, D. B. (1999). Mol. Pharmacol. 56, 31-38.
35. Cohn, C. K. and Axelrod, J. (1971). Life Sci. 10, 1351-1354.
36. Chakravorty, S. G. and Halbreich, U. (1997). Psychopharmacol. Bull. 33, 229-233.
37. Scallet, A. C. (1999). Ann. NY Acad. Sci. 890, 123-132.
38. Sawada, H., Ibi, M., Kihara, T., Urushitani, M., Akaike, A., and Shimohama, S. (1998). J. Neurosci. Res. 54, 707-719.
39. Callier, S., Le Saux, M., Lhiaubet, A.-M., Di Paolo, T., Rostene, W., and Pelaprat, D. (2002). J. Neurochem. 80, 307-323.
40. Dluzen, D. E., McDermott, J. L., and Liu, B. (1996). J. Neurochem. 66, 658-666.
41. Cyr, M., Calon, F., Morissette, M., and Di Paolo, T. (2002). J. Psychiatry Neurosci. 27, 12-27.
42. Tanner, C. M., Ottman, R., Goldman, S. M., et al. (1999). JAMA 281, 341-346.
43. Ascherio, A., Zhang, S. M., Hernan, M. A., et al. (2001). Ann. Neurol. 50, 56-63.
44. Marder, K., Tang, M.-X., Alfaro, B., et al. (1998). Neurology 50, 1141-1143.
45. Benedetti, M. D., Maraganore, D., Bower, J. H., et al. (2001). Mov. Disord. 16, 830-837.
46. Alexander, G. E., Crutcher, M. D., and DeLong, M. R. (1990). Prog. Brain Res. 85, 119-146.
47. Quinn, N. P. and Marsden, C. D. (1986). Mov. Disord. 1, 85-87.
48. Giladi, N. B. and Honigman, S. (1995). Neurology 45, 1028-1029.
49. Schipper, H. M. (1986). Neurol. Clin. 4, 721-751.
50. Bedard, P., Langelier, P., and Villeneuve, A. (1977). Lancet 2, 1367, 1368.
51. Koller, W. C., Barr, A., and Biary, N. (1982). Neurology 32, 547-549.
52. Session, D. R., Pearlstone, M. M., Jewelewicz, R., and Kelly, A. C. (1994). Med. Hypotheses 42, 280-282.
53. Komplioti, K., Comella, C., Jaglin, J. A., Leurgans, S., Raman, R., and Goetz, C. G. (2000). Neurology 55, 1572-1575.
54. Blanchet, P. J., Fang, J., Hyland, K., Arnold, L. A., Mouradian, M. M., and Chase, T. N. (1999). Neurology 53, 91-95.
55. Strijks, E., Kremer, J. A. M., and Horstink, M. W. I. M. (1999). Clin. Neuropharmacol. 22, 93-97.
56. Boudikova, B., Szumlanski, C., Maidak, B., and Weinshilboum, R. (1990). Clin. Pharmacol. Ther. 48, 381-389.
57. Grandbois, M., Morissette, M., Callier, S., and Di Paolo, T. (2000). Neuroreport 11, 343-346.
58. Jacobs, D. M., Tang, M. X., Stern, Y., et al. (1998). Neurology 50, 368-373.
59. Shaywitz, S. E., Shaywitz, B. A., Pugh, K. R., et al. (1999). JAMA 281, 1197-1202.
60. Rehman, H. U. and Masson, E. A. (2001). Age Ageing 30, 279-287.
61. Okun, M. S., McDonald, W. M., and DeLong, M. R. (2002). Arch. Neurol. 59, 807-811.
62. Veliskova, J. and Moshe, S. L. (2001). Ann. Neurol. 50, 596-601.
63. Mayeux, R., Chen, J., Mirabello, E., et al. (1990). Neurology 40, 1513-1517.
64. Brown, R. G. and Marsden, C. D. (1984). Lancet 2, 1262-1265.
65. Lees, A. J. and Smith, E. (1983). Brain 106, 257-270.
66. Brown, R. G. and Marsden, C. D. (1990). Trends Neurosci. 13, 21-29.
67. Levin, B. E., Llabre, M. M., and Weiner, W. J. (1989). Neurology 39, 557-561.
68. Sherwin, B. B. (1988). Psychoneuroendocrinology 13, 345-347.
69. Verghese, J., Kuslansky, G., Katz, M. J., et al. (2000). Neurology 55, 872-874.
70. Writing Group for the Women's Health Initiative Investigators. (2002). JAMA 288(3), 321-333.